Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071904
Chunk: 76

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 76
---
 Facility. Liquidity and Capital Resources As of March 31, 2025, we had cash and cash equivalents of approximately $5.8 million. We have funded our operations primarily through the financing pursuant to the ATM Sales Agreement (as defined below). We also have indebtedness pursuant to the Oramed Note and Tranche B Notes as well as deferred consideration related to the GLOPERBA license acquired from Romeg in 2022. The following table summarizes the aggregate indebtedness of these issuances as of March 31, 2025 and December 31, 2024 (in thousands):

| Oramed Note (outstanding principal balance: $25.7 million and $25.0 million as of March 31, 2025 and December 31, 2024, respectively)     |     | March 31, 2025 | 14,962 |     | December 31, 2024 | 12,161 |
|:------------------------------------------------------------------------------------------------------------------------------------------|:----|:---------------|-------:|:----|:------------------|-------:|
| Tranche B Notes (outstanding principal balance: $37.0 million and $38.0 million as of March 31, 2025 and December 31, 2024, respectively) |     |                | 24,480 |     |                   | 23,560 |
| Purchased Revenue Liability                                                                                                               |     |                |  7,300 |     |                   |  6,800 |
| Deferred Consideration with Romeg                                                                                                         |     |                |  2,780 |     |                   |  2,895 |
| Total indebtedness                                                                                                                        |     | $              | 49,522 |     | $                 | 45,416 |

<div align='center'>43</div>

Oramed Note

As of March 31, 2025, the fair value of the Oramed Note outstanding was $15.0 million pursuant to the Scilex-Oramed SPA (see Note 7 titled “Debt”to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information).

Tranche B Notes

As of March 31, 2025, the fair value of the Tranche B Notes outstanding was $24.5 million pursuant to the Tranche B Securities Purchase Agreement (see Note 7 titled “Debt” to our unaudited condensed consolidated financial statements included elsewhere